Profile data is unavailable for this security.
About the company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
- Revenue in USD (TTM)0.00
- Net income in USD-75.80m
- Incorporated2020
- Employees51.00
- LocationNuvation Bio Inc357 Tehama Street, Floor 3SAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 754-3517
- Fax+1 (302) 636-5454
- Websitehttps://www.nuvationbio.com/
More ▼
Mergers & acquisitions
| Acquired company | NUVB:NYQ since announced | Transaction value |
|---|---|---|
| AnHeart Therapeutics Inc | 45.89% | 100.69m |
Data delayed at least 15 minutes, as of May 14 2024 00:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 773.10m | 82.00 | -- | 5.70 | -- | 315.94 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 773.37m | 180.00 | -- | 2.93 | -- | 6.21 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 774.88m | 50.00 | -- | 2.47 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 780.24m | 140.00 | -- | 2.95 | -- | 20.96 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Evolus Inc | 219.70m | -60.00m | 789.52m | 279.00 | -- | 42.58 | -- | 3.59 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 813.28m | 74.00 | -- | 4.78 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 824.65m | 158.00 | -- | 1.89 | -- | 3,325.22 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 826.69m | 284.00 | -- | 4.06 | -- | 10.22 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Nuvation Bio Inc | 0.00 | -75.80m | 831.35m | 51.00 | -- | 1.22 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 834.41m | 168.00 | -- | -- | -- | 20.57 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 852.20m | 309.00 | -- | 1.14 | -- | 24.12 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| 89bio Inc | 0.00 | -165.03m | 855.94m | 70.00 | -- | 1.62 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 861.39m | 24.00 | -- | 3.71 | -- | 28,713.04 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 872.66m | 267.00 | -- | 2.14 | -- | 14.58 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 878.21m | 3.93k | -- | 0.701 | -- | 1.10 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Data as of May 14 2024. Currency figures normalised to Nuvation Bio Inc's reporting currency: US Dollar USD
37.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 26.13m | 11.98% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 19.21m | 8.81% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 10.47m | 4.80% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.42m | 3.41% |
| Abrams Capital Management LPas of 31 Dec 2023 | 3.81m | 1.75% |
| Tang Capital Management LLCas of 31 Dec 2023 | 3.50m | 1.61% |
| Millennium Management LLCas of 31 Dec 2023 | 3.09m | 1.42% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.06m | 1.40% |
| Geode Capital Management LLCas of 31 Dec 2023 | 3.05m | 1.40% |
| Redmile Group LLCas of 31 Dec 2023 | 3.03m | 1.39% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
